Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Mark Jacobson sold 233 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $228.18, for a total value of $53,165.94. Following the completion of the transaction, the chief operating officer owned 4,517 shares in the company, valued at $1,030,689.06. This represents a 4.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Axsome Therapeutics Stock Down 0.3%

Shares of AXSM traded down $0.64 during trading hours on Tuesday, reaching $223.06. The company’s stock had a trading volume of 1,019,532 shares, compared to its average volume of 882,597. The firm has a market cap of $11.47 billion, a price-to-earnings ratio of -59.80 and a beta of 0.59. Axsome Therapeutics, Inc. has a 1-year low of $96.09 and a 1-year high of $234.29. The company has a quick ratio of 1.48, a current ratio of 1.55 and a debt-to-equity ratio of 1.38. The company has a 50 day moving average of $171.73 and a two-hundred day moving average of $163.34.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The business had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 246.90%. The company’s revenue for the quarter was up 57.4% on a year-over-year basis. As a group, research analysts predict that Axsome Therapeutics, Inc. will post -1.05 EPS for the current fiscal year.

Analyst Ratings Changes

AXSM has been the subject of several recent research reports. TD Cowen reissued a “buy” rating on shares of Axsome Therapeutics in a research note on Friday. Wolfe Research initiated coverage on Axsome Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $230.00 price target for the company. Royal Bank Of Canada boosted their price target on Axsome Therapeutics from $242.00 to $302.00 and gave the company an “outperform” rating in a research note on Tuesday. Oppenheimer set a $280.00 price target on Axsome Therapeutics in a research note on Monday. Finally, Jefferies Financial Group boosted their price target on Axsome Therapeutics from $245.00 to $275.00 and gave the company a “buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $251.89.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Very strong top-line growth — 1Q net product revenue of $191.2M, up ~57% YoY, driven by AUVELITY ($153.2M) and SUNOSI ($33.9M); this validates commercial traction for Axsome’s lead products. Axsome 1Q 2026 Financial Results
• Positive Sentiment: Multiple analyst price-target lifts today (notably Mizuho to $310, Wells Fargo to $255, Baird to $246, Morgan Stanley to $242) and continued “buy/outperform” coverage increase perceived upside and support near-term sentiment. Analyst Coverage & Price Target Moves
• Positive Sentiment: Pipeline and corporate catalysts remain in play — AUVELITY approval for agitation in Alzheimer’s, NDA submission for AXS‑12 (cataplexy), addition of AXS‑20 to the pipeline — these can drive medium/long-term upside. Business Update & Pipeline Highlights
• Neutral Sentiment: Management outreach: Axsome will participate in multiple investor conferences (BofA fireside chat, others) — useful for additional disclosure but timing/impact is uncertain. Investor Conference Participation
• Neutral Sentiment: Full earnings and call transcripts are available for deeper read-throughs; analysts and commentators are parsing sequential trends and guidance in detail. Earnings Call Transcript & Analysis
• Negative Sentiment: Earnings miss: GAAP EPS of ($1.26) vs. consensus (~$0.85 loss) — the wider loss and negative margins/ROE raise near-term profitability concerns despite revenue strength. Q1 Loss Widens; Revenues Jump (Zacks)
• Negative Sentiment: Some skepticism on sustainability — commentary notes sequential sales dips for key products and questions about achievability of management’s long‑term peak revenue targets, which could temper enthusiasm. Earnings Review & Skepticism (Seeking Alpha)

Institutional Investors Weigh In On Axsome Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Illinois Municipal Retirement Fund bought a new stake in Axsome Therapeutics during the first quarter worth approximately $884,000. Hillsdale Investment Management Inc. bought a new stake in Axsome Therapeutics during the first quarter worth approximately $9,019,000. Fifth Third Bancorp boosted its position in Axsome Therapeutics by 554.6% during the first quarter. Fifth Third Bancorp now owns 16,214 shares of the company’s stock worth $2,741,000 after purchasing an additional 13,737 shares during the period. Hsbc Holdings PLC bought a new stake in Axsome Therapeutics during the first quarter worth approximately $11,589,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in Axsome Therapeutics by 6.8% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,030 shares of the company’s stock worth $343,000 after purchasing an additional 130 shares during the period. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.